Healthcare Industry News: IMRT
News Release - June 21, 2007
Varian Medical Systems Names C. Clifton Ling as Director of Advanced Clinical ResearchPALO ALTO, Calif., June 21 (HSMN NewsFeed) -- Varian Medical Systems (NYSE: VAR ) today announced that it will appoint C. Clifton Ling, Ph.D, to the position of director of advanced clinical research for Oncology Systems. Ling, a world renowned medical physicist who has been serving as chairman and attending physicist at Memorial Sloan Kettering Cancer Center in New York, will play a key role in guiding the development of Varian's clinical products for radiotherapy and radiosurgery.
"Varian has had the privilege of collaborating with Clif Ling for many years in his role as a clinical physicist and radiation science researcher," said Tim Guertin, president and CEO of Varian. "He has been instrumental in the development of advanced treatment protocols for intensity modulated radiotherapy (IMRT) and image-guided radiotherapy (IGRT). He is respected around the world and we expect that he will be a tremendous asset to Varian in this important new role as we develop additional clinical capabilities including dynamic adaptive radiotherapy as well as protocols for biologically guided treatments."
Ling will join Varian on July 16th. He also will continue to do hypoxia imaging research on a part-time basis at Memorial Sloan Kettering Cancer Center. "I look forward to the opportunities and challenges in working with Varian to develop novel and improved tools and methods for multimodality cancer therapy," said Ling.
Ling, 64, has been the Enid Haupt Chair of Medical Physics at Memorial Sloan Kettering Cancer Center and has an extensive record of research and academic achievement. Among his numerous awards are the Coolidge Award of the American Association of Physicists in Medicine (AAPM) in 2004 and the Gold Medal of the American Society of Therapeutic Radiology and Oncology (ASTRO) in 2006, both the highest honor of the respective organization. In 1998, he was elected honorary member of the European Society of Therapeutic Radiology and Oncology (ESTRO). He has lectured as a named visiting professor at many institutions, including Harvard University/MGH, the University of California at San Francisco, Stanford University and Washington University. He has published more than 200 research papers on a broad range of topics in the radiation sciences and clinical radiotherapy, and he has contributed to dozens of books, chapters, editorials, and proceedings. Ling has served on committees, panels, and boards for the National Institute of Health, the National Cancer Institute in the U.S. and in Canada, AAPM, the National Academies, the Radiation Research Society, the American College of Radiology, ASTRO, and the Radiological Society of North America. He has served on editorial boards for Radiation Research, RadioGraphics, Medical Physics, Radiotherapy and Oncology, International Journal of Radiation Oncology Biology Physics and Seminars in Radiation Oncology. Ling earned his B.S. in Physics at Oregon State University in 1965 and his Ph.D. in Nuclear Physics at the University of Washington in Seattle in 1971.
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 4,300 people who are located at manufacturing sites in North America and Europe and in its 56 sales and support offices around the world. For more information, visit http://www.varian.com/.
Source: Varian Medical Systems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.